L vs RGNX · P/E 14, rev $18.45B vs rev $114.4M
Loews Corp (L) versus Regenxbio Inc (RGNX) — a side-by-side from cached financials, not a winner call.
Loews Corp (L) is a insurance - property & casualty company listed on NYSE.
Regenxbio Inc (RGNX) is a biotechnology company listed on US.
Latest reported L revenue for 2025-12-31 was $18.45B. Net income was $1.67B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. L currently screens at market cap $22.36B and trailing P/E 13.8.
Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.
L currently screens at market cap $22.36B and trailing P/E 13.8. RGNX currently screens at market cap $440.4M.
Not investment advice. Open the L and RGNX stock pages for the full models.
Not investment advice.